As an oncologist at Dana-Farber Cancer Institute, Erin has seen how quickly a patient’s indolent lymphoma can transform into a drug-resistant or rapidly growing cancer, making it extremely difficult to treat—a transformation poorly understood by scientists. Erin’s BroadIgnite project seeks to change this by using single-cell technologies to pinpoint the cellular changes that occur during this dramatic progression, ultimately identifying targeted treatment opportunities for aggressive lymphomas.